McN3716 (Methyl palmoxirate) is used as a carnitine palmitoyltransferase I (CPT-1) inhibitor to suppress brain mitochondrial β-oxidation; it significantly reduces the levels of various nonenzymatic auto-oxidative metabolites of arachidonic acid (ARA), including HETEs and epoxyeicosatrienoic acids (EETs), as well as hydroxyeicosapentaenoic acids derived from eicosapentaenoic acid (EPA); it also decreases the brain level of 6-keto-PGF1α, a stable metabolite of prostacyclin (PGI2).